GlassScriptPhysician profile
Robert Leland Baker
NPI 1033107750
$594.81
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18.10 · 2020: $140 · 2021: $67.62 · 2022: $80.14 · 2023: $164 · 2024: $124.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $289.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $288.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $119.04 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $76.62 | 2024 | Austedo Xr |
| Lilly USA, LLC | $68.33 | 2023-2024 | Jardiance, Mounjaro |
| Amgen INC. | $62.76 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.81 | 2023-2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $38.81 | 2021-2022 | |
| Hologic Sales and Service, LLC | $30.59 | 2023 | Thinprep 2000 Processor |
| Merck Sharp & Dohme LLC | $21.33 | 2022 | |
| Glaxosmithkline, LLC. | $20.08 | 2023 | Shingrix, Arexvy |
| Abbvie INC. | $19.70 | 2023 | Botox |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.61 | 2022 | |
| Allergan, INC. | $18.10 | 2019 | |
| Galderma Laboratories, L.P. | $14.80 | 2023 | Dysport |
| Astrazeneca Pharmaceuticals LP | $14.04 | 2022 | |
| Pfizer INC. | $12.19 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.